AAAAAA
Results:
1-13
|
Results: 13
Authors:
MONTORO JB
ALTISENT C
PICO M
CABANAS MJ
VILA M
PUIG LL
Citation: Jb. Montoro et al., RECOMBINANT FACTOR VIIA IN CONTINUOUS-INFUSION DURING CENTRAL LINE INSERTION IN A CHILD WITH FACTOR-VIII HIGH-TITER INHIBITOR, Haemophilia, 4(5), 1998, pp. 762-765
Authors:
MONTORO JB
OLIVERAS J
ALTISENT C
RUIZ I
Citation: Jb. Montoro et al., DOSE OF NON-HEAT-TREATED FACTOR-VIII CONCENTRATE AND HIV-1 RNA LEVELS, JAMA, the journal of the American Medical Association, 277(1), 1997, pp. 20-20
Authors:
PASCUAL B
MONTORO JB
Citation: B. Pascual et Jb. Montoro, COMPARATIVE-STUDY OF 4 DIFFERENT PHARMACOKINETIC COMPUTER-PROGRAMS - CASE-STUDY OF A FACTOR-VIII PREPARATION, European Journal of Clinical Pharmacology, 52(1), 1997, pp. 59-64
Authors:
FLORES G
JUAREZ JC
MONTORO JB
TUSELL JM
ALTISENT C
Citation: G. Flores et al., EFFICACY OF HIGH-TEMPERATURE DRY HEAT IN INACTIVATING PARVOVIRUS, Haemophilia, 2(1), 1996, pp. 64-64
Authors:
LOPEZ RM
AYESTARAN A
POU L
MONTORO JB
HERNANDEZ M
CARAGOL I
Citation: Rm. Lopez et al., STABILITY OF AMPHOTERICIN-B IN AN EXTEMPORANEOUSLY PREPARED IV FAT EMULSION, American journal of health-system pharmacy, 53(22), 1996, pp. 2724-2727
Authors:
MONTORO JB
LOPEZ RM
POU L
Citation: Jb. Montoro et al., COMPATIBILITY OF AMPHOTERICIN-B WITH LIPID EMULSIONS - COMMENT, The Annals of pharmacotherapy, 30(12), 1996, pp. 1501-1501
Authors:
AYESTARAN A
LOPEZ RM
MONTORO JB
ESTIBALEZ A
POU L
JULIA A
LOPEZ A
PASCUAL B
Citation: A. Ayestaran et al., PHARMACOKINETICS OF CONVENTIONAL FORMULATION VERSUS FAT EMULSION FORMULATION OF AMPHOTERICIN-B IN A GROUP OF PATIENTS WITH NEUTROPENIA, Antimicrobial agents and chemotherapy, 40(3), 1996, pp. 609-612
Authors:
ALTISENT C
MONTORO JB
RUIZ I
LORENZO JI
Citation: C. Altisent et al., LONG-TERM SURVIVORS AND PROGRESSION OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION, The New England journal of medicine, 334(16), 1996, pp. 1065-1066
Authors:
FLORES G
JUAREZ JC
MONTORO JB
TUSELL JM
ALTISENT C
JUSTE C
JARDI R
Citation: G. Flores et al., SEROPREVALENCE OF PARVOVIRUS B19, CYTOMEGALOVIRUS, HEPATITIS-A VIRUS AND HEPATITIS-E VIRUS-ANTIBODIES IN HEMOPHILIACS TREATED EXCLUSIVELY WITH CLOTTING-FACTOR CONCENTRATES CONSIDERED SAFE AGAINST HUMAN IMMUNODEFICIENCY AND HEPATITIS-C VIRUSES, Haemophilia, 1(2), 1995, pp. 115-117
Authors:
PASCUAL B
AYESTARAN A
MONTORO JB
OLIVERAS J
ESTIBALEZ A
JULIA A
LOPEZ A
Citation: B. Pascual et al., ADMINISTRATION OF LIPID-EMULSION VERSUS CONVENTIONAL AMPHOTERICIN-B IN PATIENTS WITH NEUTROPENIA, The Annals of pharmacotherapy, 29(12), 1995, pp. 1197-1201
Authors:
MONTORO JB
OLIVERAS J
LORENZO JI
TUSELL JM
ALTISENT C
MOLINA R
AYESTARAN AI
Citation: Jb. Montoro et al., AN ASSOCIATION BETWEEN CLOTTING FACTOR CONCENTRATES USE AND MORTALITYIN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED HEMOPHILIC PATIENTS, Blood, 86(6), 1995, pp. 2213-2219
Authors:
MONTORO JB
ALTISENT C
PINEDA A
RODRIGUEZ S
TUSELL JM
Citation: Jb. Montoro et al., CONTINUOUS-INFUSION OF FACTOR-VIII CONCENTRATE TO A PATIENT WITH SEVERE VONWILLEBRAND DISEASE, Transfusion, 33(5), 1993, pp. 443-443
Authors:
SANZ S
ALTISENT C
MONTORO JB
POU L
Citation: S. Sanz et al., THE PHARMACOKINETICS OF ZIDOVUDINE, Medicina Clinica, 101(18), 1993, pp. 717-717
Risultati:
1-13
|